Comparing Long-Term Efficacy of Bladder-Preserving Therapies for NMIBC

Neal Shore, MD, FACS, discuss the key efficacy outcomes reported for nadofaragene firadenovec (ADSTILADRIN) in the phase 3 trial for patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) and compare these long-term results to other bladder-preserving therapies in this population.

Now Viewing

EP: 1.Comparing Long-Term Efficacy of Bladder-Preserving Therapies for NMIBC

EP: 2.SunRISe-1: Examining Combination Therapy for HR NMIBC

EP: 3.NURE-COMBO: Patient Population, Regimen, and Efficacy in MIBC

EP: 4.Novel Therapy + 5-Year Bladder Preservation for Patients with NMIBC

EP: 5.SunRISe-1 and NURE-COMBO: Addressing Unmet Needs and Expanding Treatment Options for Bladder Cancer

EP: 6.Novel Therapies for Bladder Cancer: Safety Profiles and Study Design Considerations

EP: 7.Final Insights on Current Bladder Cancer Clinical Trials

1) What are the key efficacy outcomes reported for nadofaragene firadenovec (ADSTILADRIN) in the phase 3 trial for patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC)? How do these long-term results compare to other bladder-preserving therapies in this population?

Related Videos

Related Content

Advertisement

July 29th 2025

Chemoimmunotherapy Shows Promise for Limited-Stage SCLC in Real-World Study

AJMC Contributor

Real-world data support the effectiveness of combining platinum-based chemotherapy with PD-1 inhibitors for recurrent limited-disease small cell lung cancer (SCLC), enhancing patient outcomes.

July 24th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

July 29th 2025

Setting Care Goals Early Is Key in Pulmonary Fibrosis

AJMC Contributor

With limited treatment options and potential for admission to the intensive care unit, researchers of a new paper highlighted the importance of discussing goals and initiating palliative care early on.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 28th 2025

Long COVID More Common Among Socially Vulnerable Individuals

Brooke McCormick

Social risk factors significantly increase the likelihood of developing long COVID, highlighting the urgent need for equitable health care and support systems.

July 28th 2025

Gefurulimab for gMG Meets Key End Points in PREVAIL Trial

Marco Meglio

The primary endpoint in PREVAIL is Myasthenia Gravis-Activities of Daily Living total score improvement from baseline, and the secondary endpoints are Quantitative Myasthenia Gravis total score and Myasthenia Gravis Composite total score.

Related Content

Advertisement

July 29th 2025

Chemoimmunotherapy Shows Promise for Limited-Stage SCLC in Real-World Study

AJMC Contributor

Real-world data support the effectiveness of combining platinum-based chemotherapy with PD-1 inhibitors for recurrent limited-disease small cell lung cancer (SCLC), enhancing patient outcomes.

July 24th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

July 29th 2025

Setting Care Goals Early Is Key in Pulmonary Fibrosis

AJMC Contributor

With limited treatment options and potential for admission to the intensive care unit, researchers of a new paper highlighted the importance of discussing goals and initiating palliative care early on.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 28th 2025

Long COVID More Common Among Socially Vulnerable Individuals

Brooke McCormick

Social risk factors significantly increase the likelihood of developing long COVID, highlighting the urgent need for equitable health care and support systems.

July 28th 2025

Gefurulimab for gMG Meets Key End Points in PREVAIL Trial

Marco Meglio

The primary endpoint in PREVAIL is Myasthenia Gravis-Activities of Daily Living total score improvement from baseline, and the secondary endpoints are Quantitative Myasthenia Gravis total score and Myasthenia Gravis Composite total score.